Locoregionally advanced nasopharyngeal carcinoma: integrating immunotherapy into definitive treatment
Mené sur 150 patients atteints d'un carcinome du rhinopharynx de stade localement avancé (durée médiane de suivi : 37,8 mois), cet essai randomisé de phase II évalue l'efficacité, du point de vue de la survie sans progression à 2 ans, et la toxicité de l'ajout, à une chimioradiothérapie concomittante, du toripalimab (un anti-PD-1) en traitement néoadjuvant puis adjuvant
Chemoradiotherapy has remained the standard of care for advanced nasopharyngeal carcinoma for more than two decades without achieving a major breakthrough in terms of improved outcomes. Following the success of combining chemotherapy with checkpoint inhibitors for treating recurrent or metastatic nasopharyngeal carcinoma,1–3 checkpoint inhibitor integration has become a major interest for the definitive treatment of this disease.
The Lancet Oncology 2023